Creatv Bio's LifeTracDx® Liquid Biopsy Predicts Response to New Line of Therapy for Metastatic Breast Cancer within 30 Days

Results to be presented at ASCO 2022 Annual Meeting in Chicago, ILROCKVILLE, Md.--(BUSINESS WIRE)--Creatv Bio, Division of Creatv MicroTech, Inc., announced today the release of an abstract featuring the results of its LifeTracDx® blood test for predicting response of metastatic breast cancer (mBC) to new lines of t...

Related Keywords

Rockville ,Illinois ,United States ,Chicago ,American ,Creatv Lifetracdx ,Daniell Adams ,Creatv Bio ,Division Of Creatv Microtech ,Research Use ,American Society Of Clinical Oncology ,Division Of Creatv Microtech Inc ,Nasdaq ,Briacell Therapeutics Corp ,Creatv Microtech ,Clinical Oncology ,Annual Meeting June ,Briacell Therapeutics ,Developmental Therapeutics ,Molecularly Targeted Agents ,Tracking Changes ,Circulating Stromal Cells ,Circulating Tumor Cells Predicts Responsiveness ,New Line Induction ,Metastatic Breast Cancer ,Creatv Bio Director ,Giuseppe Del Priore ,Chief Medical Officer ,Research Use Only ,Circulating Tumor Cells ,Cancer Associated Macrophage Like Cells ,